AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Phase 2 Unknown 80 enrolled Chinese Academy of Medical Sciences Akeso Pharmaceuticals, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a two-arm, open, multicenter clinical study to evaluate the efficacy and safety of AK104 alone or in combination with cisplatin and paclitaxel in the treatment of advanced esophageal squamous carcinoma without systemic therapy.

Timeline

Start: 2022-10-01
Primary completion: 2024-04-01
Completion: 2024-10-01

Publications

Qu W, Gao J, Zhang B, Yang M, Wang Y, Liu Y, Guo Y, Guo S, Huang J. Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial. J Immunother Cancer. 2025 Oct 30;13(10):e012869. doi: 10.1136/jitc-2025-012869.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cadonilimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Summary

Timeline

Publications

Drugs

Indications